Full Study Title: The Designer D-dimer Deep Vein Thrombosis Diagnosis (4D) Study
Principal Investigator: Clive Kearon
Funding: CIHR (Canadian Institutes of Health Research)
Design: Prospective cohort study to assess a new diagnostic management strategy for suspected Deep Vein Thrombosis in outpatients
For more information: NCT02038530 https://clinicaltrials.gov/
Full Title Study: Age-adjusted D-dimer Cutoff Levels to Rule Out Deep Vein Thrombosis: a Prospective Outcome Study
Principal Investigators: Gregoire Le Gal, Marc Righini
Funding: HSF (Heart and Stroke Foundation of Canada)
Design: Prospective cohort to validate an age-adjusted D-dimer cut-off to rule out DVT (deep vein thrombosis)
For more information: NCT02384135 https://clinicaltrials.gov/
Full Study Title: AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study
Principal Investigators: Leslie Skeith, Marc Rodger
Funding: CanVECTOR Pilot, LEO (Leo Pharma)
Design: Open-label pilot RCT of antepartum prophylaxis with LMWH and ASA versus ASA alone in women with confirmed antiphospholipid syndrome (APS) and a history of past pregnancy loss
For more information: NCT03100123 https://clinicaltrials.gov/
Full Study Title: Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in Cancer Patients
Principal Investigators: Michael Kovacs
Funding: self-funded
Design: Cohort study of cancer patients with central line associated DVT (deep vein thrombosis) in the upper extremity treated with 1 week of LMWH (low-molecular-weight heparin) followed by Apixaban 5 mg bid x 3 months
For more information: NCT03100071 https://clinicaltrials.gov/
Full Study Title: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Principal Investigator: Lana Castellucci
Funding: CIHR (Canadian Institutes of Health Research)
Design: Open-label RCT (randomized clinical trial) comparing bleeding risk with rivaroxaban versus apixaban for acute treatment of VTE (venous thromboembolism)
For more information: NCT03266783 https://clinicaltrials.gov/
Full Study Title: Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism
Principal Investigators: Lana Castellucci, Thomas Ortel, David Garcia
Patient Partner: Ryan O'Connell
Funding: PCORI (Patient-Centered Outcomes Research Institute)
Design: Pragmatic open-label RCT (randomized clinical trial) comparing the safety and efficacy of rivaroxaban, apixaban and warfarin for the long-term treatment of unprovoked VTE (venous thromboembolism).
For more information: NCT03196349 https://clinicaltrials.gov/
Full Study Title: Prevalence of Post-Thrombotic Syndrome in Deep-Vein Thrombosis (DVT) Patients Treated With Dabigatran
Principal Investigators: Sam Schulman, Susan Kahn
Funding: BI (Boehringer Ingelheim Canada)
Design: Cohort of patients enrolled in RECOVER I and II to assess the prevalence of PTS (post-thrombotic syndrome) using the recently developed patient self-reported Villalta (PRV) Scale
For more information: NCT03050138 https://clinicaltrials.gov/
Full Study Title: Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Principal Investigator: Marc Rodger
Funding: CIHR (Canadian Institutes of Health Research)
Design: Prospective cohort study using the LEFt clinical decision rule and D-dimer for DVT (deep vein thrombosis) diagnosis in pregnant women who present with signs and symptoms of DVT (deep vein thrombosis)
For more information: NCT02507180 https://clinicaltrials.gov/
Full Study Title: Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer
Principal Investigators: Marc Carrier, Rebecca Auer
Funding: CIHR (Canadian Institutes of Health Research), LEO (Leo Pharma)
Design: Open-label RCT (randomized clinical trial) of extended peri-operative tinzaparin in patients with resectable colorectal cancer to improve cancer specific survival following surgical resection
For more information: NCT01455831 https://clinicaltrials.gov/
Full Study Title: Tumor-educated Platelets in Venous Thromboembolism
Principal Investigators: Noemie Kraaijpoel, Marc Carrier
Funding: CanVECTOR Pilot
Design: Pilot prospective cohort study assessing the diagnostic accuracy of platelet mRNA profiling for occult cancer in the setting of VTE (venous thromboembolism) - (primary outcome of the pilot is the recruitment rate)
For more information: NCT02739867 https://clinicaltrials.gov/
Full Study Title:
Principal Investigators: Sam Schulman
Funding: Octapharma
Design: Pilot prospective cohort study assessing the prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors
Principal Investigators: Aurélien Delluc
Co-Investigators:
Mark Crowther (Hamilton)
Sébastien Miranda (Ottawa)
Alejandro Lazo-Langner (London)
Walter Agenda (Italy)
Funding: CanVECTOR Pilot
Design: Prospective pilot cohort study investigating treatment of portal, mesenteric, and splenic vein thrombosis with rivaroxaban.
Full Study Title: StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study
Principal Investigator: Marc Rodger
Patient Partners: Rob Adriaanse, Ryan O'Connell
Funding: CIHR (Canadian Institutes of Health Research)
Design: Open-label pilot RCT (randomized clinical trial) of rosuvastatin to prevent recurrent VTE (venous thromboembolism) and reduce PTS (post-thrombotic syndrome) in patients with VTE (venous thromboembolism)
For more information: NCT02679664 https://clinicaltrials.gov/
Full Study Title: A Study to Evaluate the Safety of Withholding Anticoagulation in Patients With Subsegmental PE Who Have a Negative Serial Bilateral Lower Extremity Ultrasound
Principal Investigator: Marc Carrier
Funding: HSF (Heart and Stroke Foundation of Canada)
Design: Prospective management cohort study of patients with isolated SSPE (subsegmental pulmonary embolism), left untreated
For more information: NCT01455818 https://clinicaltrials.gov/
Principal Investigators: Marc Carrier
Funding: Pfizer
Design: Prospective cohort study assessing the use of weight-adjusted dalteparin inpatients over 90 kg with acute cancer-associated venous thromboembolism.
For more information:NCT03297359 https://clinicaltrials.gov/